Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Emergent BioSolutionsEBS -5.33%62 EV-to-OCF is 7.51 as of Sep. 10, 2026, which is 31% below its 10-year median of 10.91. GuruFocus rates EBS with a GF Score™ of 62/100 and a GF Value™ of $5.44 (Fairly Valued). The stock has 7 warning signs investors should review. Among 1,006 Drug Manufacturers companies, Emergent BioSolutions ranks better than 58.65% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Emergent BioSolutions's Enterprise Value is $733.3 Mil.
Emergent BioSolutions's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $97.7 Mil. Therefore, Emergent BioSolutions's EV-to-OCF for today is 7.51.
The historical rank and industry rank for Emergent BioSolutions's EV-to-OCF or its related term are showing as below:
EBS'
s EV-to-OCF Range Over the Past 10 Years
Min: -46.17 Med: 10.91 Max: 98.63
Current: 7.51
During the past 13 years, the highest EV-to-OCF of Emergent BioSolutions was 98.63. The lowest was -46.17. And the median was 10.91.
EBS's EV-to-OCF is ranked better than 58.65% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 10.375
vs EBS: 7.51
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Emergent BioSolutions's PE Ratio (TTM) for today is calculated as:
Emergent BioSolutions's share price for today is $5.68.
Emergent BioSolutions's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.550.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Emergent BioSolutions's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emergent BioSolutions EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Emergent BioSolutions's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Emergent BioSolutions's EV-to-OCF falls into.
Emergent BioSolutions's current Enterprise Value is $733.3 Mil.
Emergent BioSolutions's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $97.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emergent BioSolutions (EBS) has a EV-to-OCF of 7.51 as of Sep. 10, 2026. This is 31% below median its historical median of 10.91. According to the industry distribution chart, Emergent BioSolutions ranks #416 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 41.4%.
Is Emergent BioSolutions' EV-to-OCF too high?
Emergent BioSolutions' current EV-to-OCF of 7.51 is 31% below median its 10-year median of 10.91. The Drug Manufacturers industry median EV-to-OCF is 10.38. Emergent BioSolutions' value of 7.51 is 27.6% below this industry median. Based on the distribution chart, Emergent BioSolutions ranks #416 out of 1006 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Emergent BioSolutions has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Emergent BioSolutions' EV-to-OCF compare to ELTP and ANIK?
According to the Drug Manufacturers industry distribution chart, Emergent BioSolutions ranks #416 out of 1006 companies for EV-to-OCF. This puts Emergent BioSolutions in the upper half of its industry. The industry median EV-to-OCF is 10.38. Emergent BioSolutions' value of 7.51 is 27.6% below this benchmark. While the company's 10-year median is 10.91 vs. the industry median of 10.38, Emergent BioSolutions has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.38, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Emergent BioSolutions's current EV-to-OCF of 7.51 is 27.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Emergent BioSolutions's current EV-to-OCF is 7.51, which is 31% below median its own 10-year median of 10.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emergent BioSolutions stock overvalued right now?
Based on GuruFocus' analysis, Emergent BioSolutions (EBS) is currently considered Fairly Valued. The stock's GF Value™ is $5.44, compared to a current price of $5.68 — trading 4.4% above its estimated fair value. The current EV-to-OCF is 7.51, which is 31% below median its 10-year median of 10.91 and 27.6% below the Drug Manufacturers industry median of 10.38. Emergent BioSolutions' overall GF Score™ is 62/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Emergent BioSolutions (EBS), the current EV-to-OCF is 7.51 as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Emergent BioSolutions (EBS) Overvalued in 2026?
Based on GuruFocus' analysis, Emergent BioSolutions stock appears to be overvalued.
The current stock price of $5.68 is trading 4.4% above its estimated GF Value™ of $5.44.
GuruFocus considers Emergent BioSolutions to be Fairly Valued.
Key valuation signals for EBS:
EV-to-OCF: 7.51 (31% below median its 10-year median of 10.91)
GF Value™: $5.44 vs. price of $5.68 (4.4% above fair value)
Industry Position: 27.6% below the Drug Manufacturers median (#416 of 1006)
No single metric tells the full story. See the EBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
62GF Score
Get the complete analysis for EBS
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EBS has been successfully added to your 
